The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.
FDA grants accelerated approval for Alzheimer’s drug
June 9, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022